Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1

285Citations
Citations of this article
182Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Preeclampsia is a complication of pregnancy with significant morbidity and mortality for the mother and the fetus. Presumptions are made that placental hypoxia has a causative role in the clinical syndrome. Furthermore, soluble fms-like tyrosine kinase 1 (sFLT-1) has been shown to have a role in the maternal syndrome of preeclampsia. We investigated the relationship between uteroplacental ischemia (UPI), the maternal clinical syndrome of preeclampsia and sFLT-1 in non-human primates. The induction of UPI in a pregnant non-human primate resulted in the development of a clinical entity analogous to human preeclampsia. This was illustrated by the increase in blood pressure, development of proteinuria, and renal histological changes identical to human preeclampsia. A significant elevation in the placental and peripheral blood mononuclear cell sFLT-1 mRNA expression was noted, translating to a significant elevation in circulating sFLT-1. Thus, this sequence suggests that a pathogenic reduction in placental perfusion results in the development of the maternal syndrome of preeclampsia and an increase in circulating sFLT-1, which is derived both from placental and extra-placental sources. © 2007 International Society of Nephrology.

Cite

CITATION STYLE

APA

Makris, A., Thornton, C., Thompson, J., Thomson, S., Martin, R., Ogle, R., … Hennessy, A. (2007). Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney International, 71(10), 977–984. https://doi.org/10.1038/sj.ki.5002175

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free